ArticleScientific reports2025
Porphyrinic MOF-derived novel nanocomposite for gastric anticancer and Helicobacter pylori photoantibacterial effect assay.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porphyrinic MOF-based nanocomposites provide an applied attraction that overcomes the harmful effects of existing anticancer drugs. In this work, a nanorod porphyrinic metal-organic framework, PCN-222, was synthesized to serve as a high-surface-area drug carrier with photochemical properties. This material was then used for the production of Au nanoparticles. The PCN-222/Au/DOX NCs were provided with a low dosage of doxorubicin (DOX) as a novel nanocomposite with multifunctional anti-cancer properties on gastric cancer cells. The cytotoxicity effect was surveyed with an MTT assay on the MKN-45 cell line. The Annexin-V/propidium iodide technique and the colorimetric methods were utilized for apoptosis detection and caspase 8 and 9 pathway determination, respectively. The produced intracellular reactive oxygen species (ROS) were assigned using flow cytometry. Besides, the antibacterial activity of the nanocomposite was examined by conducting minimum inhibitory concentration (MIC) and Minimum Bactericidal Concentration (MBC) tests on Helicobacter pylori under LED light and dark conditions. Achieving a 91% ratio of the apoptotic cells versus the total dead cells rate, the high ROS production with the main Florence intensity (MIF) value of about 247.5, and an approximately two-fold increase in caspase 9 compared to caspase 8, with a MIC value of 375 µg/mL result under LED light for antibacterial activity, make the PCN-222/Au/DOX NCs an applicable promising agent with anticancer properties for gastric cancer cure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.